Serum proteomics of glioma: methods and applications

References

• Kleihues P, Cavanee WK. World Health Organization: Classification of Tumours. Pathology and Genetics of Tumours of the Nervous System. Barnes L, Eveson JW, Sidransky D (Eds). IARC Press, Lyon, France (2000).
   Google Scholar
• Berger M, Wilson C. (Eds). The Gliomas. WB Saunders, PA, USA (1999).
   Google Scholar
• Anderson NL, Anderson NG. The human plasma proteome history, character, and diagnostic prospects. Mol. Cell. Proteomics1, 845–867 (2002).
   PubMed Web of Science ®Google Scholar
• Anderson NL, Anderson NG. Proteome and proteomics: new technologies, new concepts, and new words. Electrophoresis19(11), 1853–1861 (1998).
   PubMed Web of Science ®Google Scholar
• Blackstock WP, Weir MP. Proteomics: quantitative and physical mapping of cellular proteins. Trends Biotechnol.17(3), 121–127 (1999).
   PubMed Web of Science ®Google Scholar
• Steel LF, Habb BB, Hanash SM. Methods of comparative proteomic profiling for disease diagnostics. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.815(1–2), 275–284 (2005).
   PubMed Web of Science ®Google Scholar
• Klose J. Protein mapping by combined isoelectric focusing and electrophoresis of mouse tissues. A novel approach to testing for induced point mutations in mammals. Humangenetik26(3), 231–243 (1975).
   PubMedGoogle Scholar
• O’Farrell PH. High resolution two-dimensional electrophoresis of proteins. J. Biol. Chem.250(10), 4007–4021 (1975).
   PubMed Web of Science ®Google Scholar
• Anderson L, Anderson NG. High resolution two-dimensional electrophoresis of human plasma proteins. Proc. Natl Acad. Sci. USA74(12), 5421–5425 (1977).
   PubMed Web of Science ®Google Scholar
• Unlu M, Morgan ME, Minden JS. Difference gel electrophoresis: a single gel method for detecting changes in protein extracts. Electrophoresis18(11), 2071–2077 (1997).
   PubMed Web of Science ®Google Scholar
• Nagele E, Vollmer M, Horth P, Vad C. 2D-LC/MS techniques for the identification of proteins in highly complex mixtures. Expert Rev. Proteomics1(1), 37–46 (2004).
   PubMed Web of Science ®Google Scholar
• Washburn MP, Wolters D, Yates JR III. Large-scale analysis of the yeast proteome by multidimensional protein identification technology. Nat. Biotechnol.19(3), 242–247 (2001).
   PubMed Web of Science ®Google Scholar
• Gygi SP, Rist B, Gerber SA, Turecek F, Gelb MH, Aebersold R. Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat. Biotechnol.17(10), 994–999 (1999).
   PubMed Web of Science ®Google Scholar
• Patterson SD, Aebersold R. Mass spectrometric approaches for the identification of gel-separated proteins. Electrophoresis16(10), 1791–1814 (1995).
   PubMed Web of Science ®Google Scholar
• Chen G, Pramanik BN. Application of LC/MS to proteomics studies: current status and future prospects. Drug Discov. Today14(9–10), 465–471 (2009).
   PubMed Web of Science ®Google Scholar
• Petricoin EF, Ardekani AM, Hitt BA et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet359, 572–575 (2002).
   PubMed Web of Science ®Google Scholar
• Powell K. Proteomics delivers on promise of cancer biomarkers. Nat. Med.9, 980 (2003).
   PubMed Web of Science ®Google Scholar
• Diamandis EP. Point: proteomics patterns in biological fluids: do they represent the future of cancer diagnostics? Clin. Chem.48(8), 1272–1275 (2003).
   Google Scholar
• Haab BB. Antibody arrays in cancer research. Mol. Cell. Proteomics4, 377–383 (2005).
   PubMed Web of Science ®Google Scholar
• Angenendt P, Kreutzberger J, Glokler J, Hoheisal JD. Generation of high density protein microarrays by cell-free in situ expression of unpurified PCR products. Mol. Cell. Proteomics5(9), 1658–1666 (2006).
   PubMed Web of Science ®Google Scholar
• Kim BK, Lee JW, Park PJ et al. The multiplex bead array approach to identifying serum biomarkers associated with breast cancer. Breast Cancer Res.11(2), 22 (2009).
   PubMed Web of Science ®Google Scholar
• Stupp R, Reni M, Gatta G, Mazza E, Vecht C. Anaplastic astrocytoma in adults. Crit. Rev. Oncol. Hematol.63(1), 72–80 (2007).
   PubMed Web of Science ®Google Scholar
• Reardon DA, Wen PY. Therapeutic advances in the treatment of glioblastoma: rationale and potential role of targeted agents. Oncologist11(2), 152–164 (2006).
   PubMed Web of Science ®Google Scholar
• Petrik V, Saadoun S, Loosemore A et al. Serum α2-hs glycoprotein predicts survival in patients with glioblastoma. Clin. Chem.54(4), 713–722 (2008).
   PubMed Web of Science ®Google Scholar
• Zhang H, Wu G, Tu H et al. Discovery of serum biomarkers in astrocytoma by SELDI–TOF MS and proteinchip technology. J. Neurooncol.84(3), 315–332 (2007).
   PubMedGoogle Scholar
• Azok J, Guccione S, Lim M et al. The use of magnetic resonance imaging to guide the analysis of serum proteomic patterns in glioblastoma multiforme. Proc. Intl. Soc. Mag. Reson. Med.11, 220 (2004).
   Google Scholar
• Tanwar MK, Gilbert MR, Holland EC. Gene expression microarray analysis reveals YKL-40 to be a potential serum marker for malignant character in human glioma. Cancer Res.62(15), 4364–4368 (2002).
   PubMed Web of Science ®Google Scholar
• Reddy PS, Umesh S, Thota B et al. PBEF1/NAmPRTase/Visfatin a potential malignant astrocytoma/glioblastoma serum marker with prognostic value. Cancer Biol. Ther.7(5), 663–668 (2008).
   PubMed Web of Science ®Google Scholar
• Hzecka A, Hzecki M. APRIL is increased in serum of patients with brain glioblastoma multiforme. Eur. Cytokine Netw.17(4), 276–280 (2006).
   Google Scholar
• Jung CS, Foerch C, Schänzer A et al. Serum GFAP is a diagnostic marker for glioblastoma multiforme. Brain130(12), 3336–3341 (2007).
   PubMed Web of Science ®Google Scholar
• Mischel PS, Nelson SF, Cloughesy TF. Molecular analysis of glioblastoma: pathway profiling and its implications for patient therapy. Cancer Biol. Ther.2(3), 242–247 (2003).
   PubMed Web of Science ®Google Scholar
• Hormigo A, Gu B, Karimi S et al. YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas. Clin. Cancer Res.12(19), 5698–5704 (2006).
   PubMed Web of Science ®Google Scholar
• Iwadate Y, Hayama M, Adachi A et al. High serum level of plasminogen activator inhibitor-1 predicts histological grade of intracerebral gliomas. Anticancer Res.28(1B), 415–418 (2008).
   PubMedGoogle Scholar
• Lin Y, Jiang T, Zhou K et al. Plasma IGFBP-2 levels predict clinical outcomes of patients with high-grade gliomas. Neuro. Oncol. DOI:10.1215/15228517-2008-114 (2009) (Epub ahead of print).
   Google Scholar
• Quaranta M, Divella R, Daniele A et al. Epidermal growth factor receptor serum levels and prognostic value in malignant gliomas. Tumori93(3), 275–280 (2007).
   PubMed Web of Science ®Google Scholar
• Fukuda ME, Iwadate Y, Machida T et al. Cathepsin D is a potential serum marker for poor prognosis in glioma patients. Cancer Res.65(12), 5190–5194 (2005).
   PubMed Web of Science ®Google Scholar
• Nano R, Capelli E, Argentina F, Facoetti A, Gerzeli G. Evaluation of serum levels of cytokines and intercellular adhesion molecule-1 (ICAM-1) in astrocytic tumours. Cell. Mol. Biol.49(4), 525–528 (2003).
   Google Scholar
• Ammirati M, Rao S, Granger G et al. Detection of TNF inhibitors (soluble receptors) in the sera and tumor cyst fluid of patients with malignant astrocytomas of the brain. Front. Biosci.6, B17–B24 (2001).
   Google Scholar
• Zheng PP, Hop WC, Sillevis Smitt PA et al. Low-molecularweight caldesmon as a potential serum marker for glioma. Clin. Cancer Res.11(12), 4388–4392 (2005).
   PubMed Web of Science ®Google Scholar
• Wrensch M, Wiencke JK, Wiemels J et al. Serum IgE, tumor epidermal growth factor receptor expression, and inherited polymorphisms associated with glioma survival. Cancer Res.66(8), 4531–4541 (2006).
   Google Scholar
• Guccione S, Yang Y, Chia Y et al. Identification of serum markers of glioblastoma multiforme patients using image-guided genomic and proteomic analysis. J. Clin. Oncol.24(18 Suppl.), 20008 (2006).
   Google Scholar
• Todaro L, Christiansen S, Varela et al. Alteration of serum and tumoral neural cell adhesion molecule (NCAM) isoforms in patients with brain tumors. J. Neurooncol.83(2), 135–144 (2007).
   PubMed Web of Science ®Google Scholar